IDH2 and glioblastoma: Survival analysis based on semi-quantitative scoring of CD73 expression in tumor cells by IHC showed significantly reduced progression-free survival (Mantel–Cox; p = 0.048) in IDH-WT glioblastoma patients (n = 58) that also had high CD73 (score ≥2) as compared to low CD73 protein expression (score ≤1) (Fig. 5E).